Average Co-Inventor Count = 4.05
ph-index = 8
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Bristol-myers Squibb Compnay (36 from 3,684 patents)
2. Vividion Therapeutics, Inc. (4 from 4 patents)
3. The Scripps Research Institute (3 from 1,187 patents)
4. Bristol-myers Squibb Pharma Company (234 patents)
40 patents:
1. 12479831 - Substituted N(-methyl-D3)pyridazine-3-carboxamide or M-(methyl-D3)-nicotinamide compounds as IL-12, IL-23 and/or IFNα modulators
2. 12365667 - Sulfone pyridine alkyl amide-substituted heteroaryl compounds
3. 12187685 - Pharmaceutical compositions comprising WRN helicase inhibitors
4. 11787779 - Sulfone pyridine alkyl amide-substituted heteroaryl compounds
5. 11771689 - Cereblon modulators and uses thereof
6. 11597721 - Heterocyclic compounds comprising pyridine useful as modulators of IL-12, IL-23 and/or IFNα responses
7. 11299494 - Substituted imidazo[1,2-b]pyridazines as interleukin-23 and interferon-α modulators
8. 11021475 - Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
9. 11021462 - Sulfone pyridine alkyl amide-substituted heteroaryl compounds
10. 10869860 - Cereblon modulators and uses thereof
11. 10781215 - Heterobicyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses
12. 10781239 - In vivo engineered cereblon protein
13. RE47929 - Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses
14. 10479793 - Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
15. 10294256 - Phosphine oxide alkyl amide substituted heteroaryl compounds as modulators of IL-12, IL-23 and/or IFN alpha responses